These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32271164)

  • 1. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
    Deng S; Sun Z; Qiao J; Liang Y; Liu L; Dong C; Shen A; Wang Y; Tang H; Fu YX; Peng H
    JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.
    Kaptein P; Slingerland N; Metoikidou C; Prinz F; Brokamp S; Machuca-Ostos M; de Roo G; Schumacher TNM; Yeung YA; Moynihan KD; Djuretic IM; Thommen DS
    Cancer Discov; 2024 Jul; 14(7):1226-1251. PubMed ID: 38563969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
    Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
    Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
    Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
    Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment.
    Wu S; Huang H; Sun R; Gao DS; Ye F; Huang J; Li E; Ni A; Lu KG; Chen K; Jiang J; Morel PA; Zhong Z; Lu B
    Cancer Res Commun; 2023 Aug; 3(8):1460-1472. PubMed ID: 37546701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
    Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
    Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-32γ potentiates tumor immunity in melanoma.
    Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors.
    Kinoshita T; Sayem MA; Yaguchi T; Kharma B; Morii K; Kato D; Ohta S; Mashima Y; Asamura H; Kawakami Y
    Cancer Sci; 2021 Apr; 112(4):1390-1401. PubMed ID: 33453147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
    Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
    Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F
    JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
    Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
    Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.